Grants and Contributions
About this information
In June 2016, as part of the Open Government Action Plan, the Treasury Board of Canada Secretariat (TBS) committed to increasing the transparency and usefulness of grants and contribution data and subsequently launched the Guidelines on the Reporting of Grants and Contributions Awards, effective April 1, 2018.
The rules and principles governing government grants and contributions are outlined in the Treasury Board Policy on Transfer Payments. Transfer payments are transfers of money, goods, services or assets made from an appropriation to individuals, organizations or other levels of government, without the federal government directly receiving goods or services in return, but which may require the recipient to provide a report or other information subsequent to receiving payment. These expenditures are reported in the Public Accounts of Canada. The major types of transfer payments are grants, contributions and \'other transfer payments\'.
Included in this category, but not to be reported under proactive disclosure of awards, are (1) transfers to other levels of government such as Equalization payments as well as Canada Health and Social Transfer payments. (2) Grants and contributions reallocated or otherwise redistributed by the recipient to third parties; and (3) information that would normally be withheld under the Access to Information Act and the Privacy Act.
$136,500.00
Jul 1, 2020
For-profit organization
Lead Optimization Studies-Phase II
953841
A lead optimization study to define a clinical candidate amongst a novel series of GPR119 agonists for the treatment of Type2 Diabetes and co-morbidities. This study has the potential to lead to the development of a first in class therapeutic for T2DM and obesity and advancement of a novel therapeutic pipeline to address co-morbidities associated with GPR119 dysregulation including NASH.
$90,000.00
Nov 1, 2019
For-profit organization
Lead Optimization Studies
937340
The project will advance our novel series of GPR119 agonists in a series of Lead optimization studies with the goal of identifying a lead candidate for T2DM and other metabolic disorders.